Latest glioblastoma multiforme Stories
LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
BETHESDA, Md., Dec. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S.
PORTLAND, Oregon, December 2, 2014 /PRNewswire/ -- GBI Research, the leading business intelligence provider, has released its latest research, "Glioblastoma Multiforme
Immune-based brain cancer diagnostic for rapid, accurate disease classification SAN RAMON, Calif., Dec.
SAN ANTONIO, Dec. 2, 2014 /PRNewswire/ -- GenSpera, Inc.
SAN DIEGO, Dec.
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.